The Identification of Multi-Target Inhibitors of Wolbachia Pipientis and Onchocerca Volvulus by Molecular Simulations

    Gabriel Chigozie Anizoba, Uzochukwu Ikemefuna Chijioke, Igboeli Chukwuduziem Prince, InnocentMary IfedibaluChukwu Ejiofor
    From the encyclopedia
    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Cetirizine →

    popular antihistamine showing promise for hair loss as an anti-inflammatory and prostaglandin inhibitor

    Image
    Studysummary This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against onchocerciasis by targeting proteins in the parasite and its endosymbiont; further research is needed to confirm their efficacy.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study focuses on identifying potential drug targets for Onchocerca volvulus and its endosymbiont Wolbachia pipientis, which cause human Onchocerciasis, a major public health issue in sub-Saharan Africa and Latin America. Using molecular docking simulations, 2,015 approved drugs were screened, leading to the identification of Adapalene, Diosmin, and Azelastine as promising multi-target inhibitors. Other compounds like Drospirenone, Alectinib, Dutasteride, and Finasteride also showed potential. The study concludes that repurposing these drugs could offer effective treatment options for onchocerciasis, with further research needed to confirm their efficacy.
    Discuss this study in the Community →